Navigation Links
Rutgers, Massachusetts General investigators find novel way to prevent drug-induced liver injury
Date:1/15/2012

NEW BRUNSWICK, N.J. Rutgers University and Massachusetts General Hospital (MGH) investigators have developed a novel strategy to protect the liver from drug-induced injury and improve associated drug safety.

In a report receiving advance online publication in the journal Nature Biotechnology, the team reports that inhibiting a type of cell-to-cell communication can protect against damage caused by liver-toxic drugs such as acetaminophen.

"Our findings suggest that this therapy could be a clinically viable strategy for treating patients with drug-induced liver injury," said Suraj Patel a postdoctoral researcher in the Center for Engineering in Medicine at MGH and the paper's lead author. "This work also has the potential to change the way drugs are developed and formulated, which could improve drug safety by providing medications with reduced risk of liver toxicity."

Drug-induced liver injury is the most common cause of acute liver failure in the U.S. and is also the most frequent reason for abandoning drugs early in development or withdrawing them from the market. Liver toxicity limits the development of many therapeutic compounds and presents major challenges to both clinical medicine and to the pharmaceutical industry.

Since no pharmaceutical strategies currently exist for preventing drug-induced liver injury, treatment options are limited to discontinuing the offending drug, supportive care and transplantation for end-stage liver failure.

The researchers investigated an approach that targets a liver's gap junctions hollow multimolecular channels that connect neighboring cells and allow direct communication between coupled cells. In the heart, gap junctions propagate the electrical activity required for synchronized contraction, but their role in the liver has not been well understood

Recent work has shown that gap junctions spread immune signals from injured liver cells to surrounding undamaged cells, amplifying inflammation and injury. The current study examined inhibiting the action of liver-specific gap junctions to limit drug-induced liver injury.

The researchers first used a strain of genetically mutated mice that lack a particular liver-specific gap junction. The mice were administered various liver-toxic drugs such as acetaminophen, a commonly used medication best known under the Tylenol brand name. Acetaminophen overdoses are the most frequent cause of drug-induced liver injury.

Compared to normal mice, those lacking liver gap junctions were fully protected against liver damage, inflammation and death caused by administration of liver-toxic drugs. The team then identified a small-molecule inhibitor of liver gap junctions that, when given with or even after the toxic drugs, protected the livers of normal mice against injury and prevented their death.

"This finding is very exciting and potentially very powerful from a number of basic science and clinical application standpoints, which we are continuing to explore," said Martin Yarmush, senior author of the report and the Paul and Mary Monroe Professor of Biomedical Engineering at Rutgers. "However, before we can think about applying this approach to patients, we need to know more about any off-target effects of gap junction inhibitors and better understand the long-term ramifications of temporarily blocking liver-specific gap junction channels."

Additionally, cell culture experiments indicated that blocking gap junctions limited the spread through liver cells of damaging free radicals and oxidative stress, suggesting a possible mechanism for the observed protection.


'/>"/>
Contact: Carl Blesch
cblesch@ur.rutgers.edu
732-932-7084 x616
Rutgers University
Source:Eurekalert  

Related medicine news :

1. Even privately insured have hard time getting psychiatric care in Massachusetts: Harvard study
2. Massachusetts health-care reform increased access to care, particularly among disadvantaged
3. Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trial
4. Study examines impact of Massachusetts health law on emergency department visits
5. Support for Massachusetts landmark health reform law rises in 2011
6. Massachusetts Study Shows Sharp Rise in Early Autism Diagnoses
7. Season of birth and celiac disease in Massachusetts children
8. Massachusetts reform hasnt stopped medical bankruptcies: Harvard study
9. Massachusetts General Hospital leading nationwide, comparative study of common bipolar medications
10. Massachusetts physician groups improving patient experience, study finds
11. Massachusetts Institute of Technology IDs new cancer drug target
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rutgers, Massachusetts General investigators find novel way to prevent drug-induced liver injury
(Date:5/31/2016)... ... ... the day, adults often find themselves reaching for a cup of coffee, an energy drink, ... for instead is a cup of Matcha green tea. Matcha is a premium green tea ... harvested from early June to mid-July, when the leaves are the most tender. , ...
(Date:5/31/2016)... ... May 31, 2016 , ... St. ... (Healthconnect) regional health information exchange, which enables physicians at SJMC’s two hospital campuses, ... from other participating organizations in the exchange. SJMC’s membership in the health information ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... DDL, Inc. ... American Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO 594-2 testing ... means of achieving a leak-free connection between two medical devices (e.g. a syringe and ...
(Date:5/31/2016)... ... May 31, 2016 , ... The successful implementation of “lean ... laboratories as well. However, laboratories have different challenges compared to manufacturing environments. , ... in the lab, METTLER TOLEDO has developed the Lean Lab Checklist . This ...
(Date:5/31/2016)... ... May 31, 2016 , ... In his latest ... personality traits in humans. Using presidential candidate Donald Trump as an example, Kalsi ... , “AstroNumerology is not about adding numbers up,” says Kalsi. “It is about ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... and Orphan Diseases, today announced that President & CEO Gerald ... SeeThru Equity MicroCap Conference   Where: ... , NY When: Tuesday, May 31 st , ... Where: Grand Hyatt Hotel, 109 East 42 nd St, ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
Breaking Medicine Technology: